Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled Trial

The purpose of this study is:

1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.
2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension.
3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

Inclusion Criteria:

• Age between 35-65 years old, male or female;
• Grade 1 essential hypertension;
• Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;
• Sign the informed consent;

Exclusion Criteria:

• Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR<60ml/(min·1. 73m2);
• Gastrointestinal diseases, which may affect drug absorption;
• Be allergic to the clinical trial medicine;
• Pregnant or breastfeeding women, men who plan to give birth within half a year;
• Combined with other serious primary diseases or malignant tumors;
• Hyperlipidemia with or without taking lipid-lowering drugs;
• Combined with left ventricular hypertrophy, ABI < 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;
• Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);
• Other serious conditions in which is not fit for the study.